Zydus Lifesciences has introduced ANVIMO, a breakthrough medication for preventing Cytomegalovirus (CMV) infection in haematopoietic stem cell and kidney transplant patients. The drug, containing Letermovir, offers a significant advancement in transplant care by providing a safer and more cost-effective treatment option.
The shares of Zydus Lifesciences Limited were trading at ₹877.90 up by ₹6.25 or 0.72 per cent on the NSE today at 10.25 am.
The company has dramatically reduced the cost of CMV prophylaxis by 91 per cent, bringing down the monthly treatment price from over ₹5 lakh to a substantially more affordable level. ANVIMO is available in 240 mg and 480 mg dosages and has established bioequivalence with the reference drug.
- Also read: Gold Rate Today, March 5 2025
CMV infection is a critical complication in transplant patients, potentially causing graft failure and prolonged hospital stays. Previous treatments like ganciclovir and valganciclovir had notable limitations, including toxicity and bone marrow suppression. Letermovir presents a well-tolerated alternative with improved safety profiles.
Dr Sharvil Patel, Managing Director of Zydus Lifesciences, emphasised the company’s commitment to delivering accessible healthcare solutions. The launch aims to improve survival rates and quality of life for transplant patients by making essential treatment more attainable.
